Evidence map›Paper›PMID 8760368›Full record

ArticleThe Biochemical journal1996

Immunological characterization of eristostatin and echistatin binding sites on alpha IIb beta 3 and alpha V beta 3 integrins.

C Marcinkiewicz, L A Rosenthal, D M Mosser, T J Kunicki, S Niewiarowski

Open access · bronzeAbstract read
In one paragraph

Article in The Biochemical journal, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

C MarcinkiewiczDepartment of Physiology, Sol Sherry Thrombosis Research Center, Philadelphia, PA 19140, USA.
L A Rosenthal
D M Mosser
T J Kunicki
S Niewiarowski
Temple University · USThrombosis Research Institute · GBScripps Research Institute · US

Funding

MOLECULAR BIOLOGY OF THE THROMBOCYTE FIBRINOGEN RECEPTORR01HL046979 · NHLBI · SCRIPPS RESEARCH INSTITUTE · PI KUNICKI, THOMAS J · 1992 to 2004
$1.8M
STRUCTURAL REQUIREMENTS OF KININOGEN NEUTROPHIL INTERACTIONSP50HL045486 · NHLBI · TEMPLE UNIVERSITY · 1991 to 1995
–
NHLBI NIH HHS HL 45486NHLBI NIH HHS HL 46979
6 · The paper itself

Abstract

Two disintegrins with a high degree of amino acid sequence similarity, echistatin and eristostatin, showed a low level of interaction with Chinese hamster ovary (CHO) cells, but they bound to CHO cells transfected with alpha IIb beta 3 genes (A5 cells) and to CHO cells transfected with alpha v beta 3 genes (VNRC3 cells) in a reversible and saturable manner. Scatchard analysis revealed that eristostatin bound to 816000 sites per A5 cell (Kd 28 nM) and to 200000 sites (Kd 14 nM) per VNRC3 cell respectively. However, VNRC3 cells did not bind to immobilized eristostatin. Echistatin bound to 495000 sites (Kd 53 nM) per A5 cell and to 443000 sites (Kd 20 nM) per VNRC3 cell. As determined by flow cytometry, radiobinding assay and adhesion studies, binding of both disintegrins to A5 cells and resting platelets and binding of echistatin to VNRC3 cells resulted in the expression of ligand-induced binding sites (LIBS) on the beta 3 subunit. Eristostatin inhibited, more strongly than echistatin, the binding of three monoclonal antibodies: OPG2 (RGD motif dependent), A2A9 (alpha IIb beta 3 complex dependent) and 7E3 (alpha IIb beta 3 and alpha v beta 3 complex dependent) to A5 cells, to resting and to activated platelets and to purified alpha IIb beta 3. Experiments in which echistatin and eristostatin were used alone or in combination to inhibit the binding of 7E3 and OPG2 antibodies to resting platelets suggested that these two disintegrins bind to different but overlapping sites on alpha IIb beta 3 integrin. Monoclonal antibody LM 609 and echistatin seemed to bind to different sites on alpha v beta 3 integrin. However, echistatin inhibited binding of 7E3 antibody to VNRC3 cells and to purified alpha v beta 3 suggesting that alpha v beta 3 and alpha IIb beta 3 might share the same epitope to which both echistatin and 7E3 bind. Eristostatin had no effect in these systems, providing further evidence that it binds to a different epitope on alpha v beta 3.

Indexed as

AnimalsBinding SitesCHO CellsCricetinaeEpitopesHumansIntercellular Signaling Peptides and ProteinsPeptidesPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexReceptors, VitronectinViper VenomsechistatinEpitopeseristostatinIntercellular Signaling Peptides and ProteinsPeptidesPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexReceptors, VitronectinViper Venoms

Identifiers

PMID8760368
PMCPMC1217558
OpenAlexW161576220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.